27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Biotech Replimune Group, Inc. (NASDAQ:REPL), which conducts research and cancer treatment studies using oncolytic viruses, picked up a sell-side bull Tuesday.
The Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
BMO Capital Markets analyst Do Kim initiated coverage of Replimune Group with an Outperform rating and $31 price target.
The Thesis
Replimune has developed RP1, a treatment for large injected and uninjected tumors using oncolytic viruses. BMO considers the company to be low-risk because of the treatment’s similarity to T-Vec, the only FDA-approved virus of a similar nature, Kim said in the initiation note. (See the analyst's track record here.)
“We believe RP1 can deliver on heightened expectations for oncolytic viruses, with the advent of immunotherapy, which should expose tumors to greater systemic immune activity," the analyst said.
With a stronger potency compared to T-Vec, RP1 should achieve greater benefits than those revealed in T-Vec studies, Kim said.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
The study of RP1 will additionally evaluate bladder cancer, nonmelanoma skin cancer and MSI-H cancers, Kim said. Pending clinical data, the treatment could be as effective in these tumor types, Kim said, adding that the MSI-H market opportunity could replicate that of melanoma.
Since the treatment is versatile, Replimune is able to market to a variety of patients, the analyst said.
“An important characteristic of oncolytic viruses is genetic engineering, which enables tumor selective targeting and expression of biologic therapies, including antibodies, ligands and cytokines."
Price Action
Replimune shares were down 0.18 percent at $17.07 at the time of publication Tuesday.
Related Links:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs
Regeneron To Make $100M bluebird bio Investment In Cancer Research Collaboration
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.